's management team is one of the most questionable we have ever seen at a public company. Top executives have extensive ties to alleged pump & dump schemes, organized crime and various acts of fraud.
President & Co-Founder Michael Salaman was alleged by the FTC to have engaged in scheme to sell credit card information without authorization.
He has an extensive career in penny stock failures alongside his father, Abraham Salaman, a twice-convicted fraudster w/ mob ties
At Michael Salaman’s last public company, Skinny Nutritional Corp, he selected a CFO who had previously spent 3 years in prison for bank fraud.
A key shareholder/landlord, known as “the Godfather of payday lending” was later sentenced to 14 years in prison.
All the Skinny Nutritional Corp directors resigned amidst securities fraud allegations and complaints that management failed to provide the board with basic financial information. The company eventually filed for bankruptcy.
CEO Darren Lampert is a lawyer turned penny stock broker. Lampert spent the former half of his career defending several boiler rooms & individuals with ties to the mob & the second half operating at brokerages, including some that came under scrutiny from regulators.
For example, CEO Lampert has personal and business ties to Robert Cattogio, who was sentenced to 12 years in prison in 2001 in what the government at the time dubbed “the largest securities fraud ever prosecuted”.
CEO Lampert later worked at several questionable trading operations including Hold Brothers (expelled by FINRA) and Incremental Capital (founders were arrested for insider trading).
CFO Monty Lamirato has previously been sanctioned by the SEC over allegations of professional misconduct. He had a history of working for failing penny stock companies prior to joining GrowGen
's auditor Plante & Moran was reported to have missed major fraud at one of its key clients.
Its latest PCAOB inspection report detailed a laundry list of audit failures and some of the firm’s clients consist of failing OTC companies
Purely on a fundamental basis, we see 60% downside to shares of after its recent impressive stock run and its strong quarterly sales numbers.
The company trades at an extremely rich 60.5x adjusted estimated 2020 EBITDA and over 6.1x estimated 2020 sales.
management seems to agree with our valuation assessment. The company completed a financing at $5.60 per share, reflecting a 70% discount to current levels.
Insiders and key holders have sold stock aggressively this year in the $4-$8 range
$EQIX is an $80 billion market cap data center REIT with over 260 facilities globally.
It has 10,000+ customers, ranging from small businesses to large cloud “hyperscaler” providers like Amazon, Microsoft and Google.
(2/x)
Even if you ignore our findings & take the financials of $EQIX at face value, the company trades at elevated levels; an ~86% premium to its peers on a price to forward AFFO basis and a ~59% premium on a price to forward FFO basis.
Our 4-month investigation into Temenos, involving interviews with 25 former employees, including senior leaders at the company, uncovered hallmarks of manipulated earnings and major accounting irregularities.
(2/n)
This includes evidence of roundtripped revenue, sham partnerships, rampant pulling forward of contract renewals, backdated contracts, excessive capitalization of seemingly non-existent R&D investments, and other classic accounting red flags.
$RENB is a biotech company with several preclinical drug candidates that is “committed to curing people with cancers and infectious diseases”.
Weeks ago, it voted to merge with “AI Health” company GEDi Cube, giving the company a pro-forma diluted market cap of ~$567m.
(2/n)
CEO Dr. Mark Dybul has a prestigious background:
(i) serving under Anthony Fauci at the National Institute of Health (NIH)
(ii) as Executive Director of the Global Fund to Fight AIDS, Tuberculosis, and Malaria and
(iii) as a tenured professor at Georgetown University
LifeStance is a $2.3 billion market cap mental health provider with 6,400 clinicians located across 33 U.S. states.
The company has grown its clinician base at 18% per year in a behavioral health market forecasted to grow ~5% per year until 2030. (2/n)
$LFST trades at a ~23% premium to its peers in the behavioral health industry, despite reporting in its most recent Q3 ’23 report: $188 million in losses over the last twelve months, $482 million in debt and lease obligations and a $716 million accumulated deficit.
In its complaint, the SEC alleges Mmobuosi and other defendants “booked billions of dollars’ worth of fictitious transactions through two Nigerian subsidiary companies Mmobuosi founded and controls”.
The complaint called Tingo Mobile a “sham” and “a fiction”, alleging that claimed assets, revenues, expenses, customers, and suppliers of Tingo Mobile were “virtually entirely fabricated” – and that the public co’s that control it have been “perpetrating an ongoing fraud”.